Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer
| Autor: | Viviane Hess, M Toepfer, Thomas Ruhstaller, R. Burkhard, R. von Moos, Dieter Koeberle, J Neuweiler, L. Terraciano, F. Heitzmann, C Rust, Ralph Winterhalder, G. Bieri |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Organoplatinum Compounds Colorectal cancer medicine.medical_treatment Population Urology Adenocarcinoma Deoxycytidine Drug Administration Schedule Pelvis Capecitabine Clinical Studies Antineoplastic Combined Chemotherapy Protocols medicine Rectal Adenocarcinoma Humans education rectal cancer Neoadjuvant therapy Aged education.field_of_study business.industry Rectal Neoplasms capecitabine oxaliplatin Middle Aged medicine.disease Combined Modality Therapy Neoadjuvant Therapy Surgery Oxaliplatin Oncology Fluorouracil Chemotherapy Adjuvant radiochemotherapy Female business Chemoradiotherapy medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | This multicentre phase II study evaluated the efficacy and safety of preoperative capecitabine plus oxaliplatin and radiotherapy (RT) in patients with locally advanced rectal cancer (T3/T4 rectal adenocarcinoma with or without nodal involvement). Treatment consisted of one cycle of XELOX (capecitabine 1000 mg m(-2) bid on days 1-14 and oxaliplatin 130 mg m(-2) on day 1), followed by RT (1.8 Gy fractions 5 days per week for 5 weeks) plus CAPOX (capecitabine 825 mg m(-2) bid on days 22-35 and 43-56, and oxaliplatin 50 mg m(-2) on days 22, 29, 43 and 50). Surgery was recommended 5 weeks after completion of chemoradiotherapy. The primary end point was pathological complete tumour response (pCR). Sixty patients were enrolled. In the intent-to-treat population, the pCR rate was 23% (95% CI: 13-36%). 58 patients underwent surgery; R0 resection was achieved in 57 (98%) patients, including all 5 patients with T4 tumours. Sphincter preservation was achieved in 49 (84%) patients. Tumour and/or nodal downstaging was observed in 39 (65%) patients. The most common grade 3/4 adverse events were diarrhoea (20%) and lymphocytopaenia (43%). Preoperative capecitabine, oxaliplatin and RT achieved encouraging rates of pCR, R0 resection, sphincter preservation and tumour downstaging in patients with locally advanced rectal cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|